The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer

He, Luying; Kang, Qianming; Chan, Kang Cheung; Zhang, Yang; Zhong, Zhangfeng; Tan, Wen

doi:10.3389/fimmu.2022.1093990

Cited by 33 publications

(12 citation statements)

References 324 publications

(379 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the genes reported here to be associated with offspring atopic disorders (see Table 2) are involved in the immune system or in inflammation ( HLA‐DRB1 , 81 HLA‐DRB5 , 82 IFNG , 83 SH2B3 , 84 AHR , 85 AHRR , 86 LRCH1 , 87 TLR7 , 88 MMP9 , 89 MMP27 , 90 and isoform GR‐P 91 ). Other genes are involved in basic biological processes with some associations to development ( HDAC4 , 92 C18orf1 , 93 KITL1 , 94 and MMP9 89 ) or atopic disorders ( PRKCA , 95 DPP10 , 96 and ORMDL3 97 ). None of these genes has been examined in animal or in vitro studies yet, as far as we know.…”

Section: Discussionmentioning

confidence: 89%

Childhood atopic disorders in relation to placental changes—A systematic review and meta‐analysis

Bakoyan,

Cao,

Hansson

et al. 2024

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Fetal programming may arise from prenatal exposure and increase the risk of diseases later in life, potentially mediated by the placenta. The objective of this systematic review was to summarize and critically evaluate publications describing associations between human placental changes and risk of atopic disorders during childhood. The review adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐analysis guidelines. The inclusion criteria were original research articles or case reports written in English describing a human placental change in relation to disease occurring in offspring during childhood. The MEDLINE and EMBASE databases were searched for eligible studies. Risk of bias (RoB) was assessed using the ROBINS‐I tool. The results were pooled both in a narrative way and by a meta‐analysis. Nineteen studies were included (n = 12,997 participants). All studies had an overall serious RoB, and publication bias could not be completely ruled out. However, five studies showed that histological chorioamnionitis in preterm‐born children was associated with asthma‐related problems (pooled odds ratio = 3.25 (95% confidence interval = 2.22–4.75)). In term‐born children, a large placenta (≥750 g) increased the risk of being prescribed anti‐asthma medications during the first year of life. Placental histone acetylation, DNA methylation, and gene expression differences were found to be associated with different atopic disorders in term‐born children. There is some evidence supporting the idea that the placenta can mediate an increased risk of atopic disorders in children. However, further studies are needed to validate the findings, properly control for confounders, and examine potential mechanisms.

show abstract

Section: Discussionmentioning

confidence: 89%

Childhood atopic disorders in relation to placental changes—A systematic review and meta‐analysis

Bakoyan,

Cao,

Hansson

et al. 2024

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…Matrix metalloproteinase-9 (MMP-9) is a Matrix metalloproteinase that helps degrade parts of the extracellular matrix and has also been found to be involved in processes such as inflammation, cancer invasion and metastasis 41 . Luying He et al also found that MMP9 can also regulate the activity and distribution of a variety of immune cells to affect the function of the immune system, leading to a poor prognosis of cancer 42 .…”

Section: Discussionmentioning

confidence: 99%

Single-cell RNA sequencing explores the evolution of the ecosystem from leukoplakia to head and neck squamous cell carcinoma

Wang,

Guan,

Zheng

2024

Sci Rep

View full text Add to dashboard Cite

It has been found that progression from leukoplakia to head and neck squamous cell carcinoma (HNSCC) is a long-term process that may involve changes in the multicellular ecosystem. We acquired scRNA-seq samples information from gene expression omnibus and UCSC Xena database. The BEAM function was used to construct the pseudotime trajectory and analyze the differentially expressed genes in different branches. We used the ssGSEA method to explore the correlation between each cell subgroup and survival time, and obtained the cell subgroup related to prognosis. During the progression from leukoplakia to HNSCC, we found several prognostic cell subgroups, such as AURKB + epithelial cells, SFRP1 + fibroblasts, SLC7A8 + macrophages, FCER1A + CD1C + dendritic cells, and TRGC2 + NK/T cells. All cell subgroups had two different fates, one tending to cell proliferation, migration, and enhancement of angiogenesis capacity, and the other tending to inflammatory immune response, leukocyte chemotaxis, and T cell activation. Tumor-promoting genes such as CD163 and CD209 were highly expressed in the myeloid cells, and depletion marker genes such as TIGIT, LAG3 were highly expressed in NK/T cells. Our study may provide a reference for the molecular mechanism of HNSCC and theoretical basis for the development of new therapeutic strategies.

show abstract

“…Nearly all ECM components could be degraded by matrix metalloproteinases (MMPs), a class of calcium and zinc-dependent proteolytic enzymes [ 156 ]. MMPs could be secreted by macrophages [ 157 ]. A breast cancer study revealed that CAR-147 macrophages reduced collagen deposition in tumors and enhanced T cell infiltration into tumors, leading to a suppression of human epidermal growth factor receptor 2 (HER2)-4T1 tumor growth in mice [ 158 ].…”

Section: Challenges and Strategies Of Act In Solid Tumorsmentioning

confidence: 99%

The potential and promise for clinical application of adoptive T cell therapy in cancer

Li,

Zheng,

Liu

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Adoptive cell therapy has revolutionized cancer treatment, especially for hematologic malignancies. T cells are the most extensively utilized cells in adoptive cell therapy. Currently, tumor-infiltrating lymphocytes, T cell receptor-transgenic T cells and chimeric antigen receptor T cells are the three main adoptive T cell therapies. Tumor-infiltrating lymphocytes kill tumors by reinfusing enlarged lymphocytes that naturally target tumor-specific antigens into the patient. T cell receptor-transgenic T cells have the ability to specifically destroy tumor cells via the precise recognition of exogenous T cell receptors with major histocompatibility complex. Chimeric antigen receptor T cells transfer genes with specific antigen recognition structural domains and T cell activation signals into T cells, allowing T cells to attack tumors without the assistance of major histocompatibility complex. Many barriers have been demonstrated to affect the clinical efficacy of adoptive T cell therapy, such as tumor heterogeneity and antigen loss, hard trafficking and infiltration, immunosuppressive tumor microenvironment and T cell exhaustion. Several strategies to improve the efficacy of adoptive T cell therapy have been explored, including multispecific chimeric antigen receptor T cell therapy, combination with immune checkpoint blockade, targeting the immunosuppressive tumor microenvironment, etc. In this review, we will summarize the current status and clinical application, followed by major bottlenecks in adoptive T cell therapy. In addition, we will discuss the promising strategies to improve adoptive T cell therapy. Adoptive T cell therapy will result in even more incredible advancements in solid tumors if the aforementioned problems can be handled. Graphical abstract

show abstract

The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer

Cited by 33 publications

References 324 publications

Childhood atopic disorders in relation to placental changes—A systematic review and meta‐analysis

Childhood atopic disorders in relation to placental changes—A systematic review and meta‐analysis

Single-cell RNA sequencing explores the evolution of the ecosystem from leukoplakia to head and neck squamous cell carcinoma

The potential and promise for clinical application of adoptive T cell therapy in cancer

Contact Info

Product

Resources

About